News & Investors
News
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer
LUMISIGHT™ and Lumicell™ Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may have been otherwise missed during lumpectomy surgery, while sparing some from
Lumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual Meeting
Key Studies Examined the Benefits of Intraoperative Imaging Using Investigational Agent LUMISIGHT™ in Combination with Lumicell™ Direct Visualization System (DVS) NEWTON, Mass., March 25, 2024—Lumicell Inc., a privately held
Lumicell Announces FDA Advisory Committee’s Positive Recommendation on the Benefit-Risk Profile of LUMISIGHT™ in the Detection of Cancerous Tissue During Breast Conserving Surgery
NEWTON, Massachusetts – Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer, today announced the Medical Imaging Drugs Advisory Committee (MIDAC) of the U.S Food
Lumicell Announces Initial Data Demonstrating LUMISIGHT™’s Ability to Detect Tumors Metastasized to Multiple Organs in the Peritoneum
Promising feasibility study results for imaging technology that identified malignant peritoneal tumor metastasis during surgery NEWTON, Mass.–(BUSINESS WIRE)–Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies
Lumicell Co-Founder Moungi Bawendi Awarded Nobel Prize in Chemistry
Bawendi’s expertise in optics, fluorescent molecules and tissue imaging were instrumental in development of Lumicell Direct Visualization System, which is currently under FDA review NEWTON, Mass., October 5, 2023—Lumicell, Inc.,
Lumicell Announces FDA Acceptance and Priority Review of New Drug Application for LUMISIGHT™ Optical Imaging Agent for Breast Cancer
NEWTON, Mass., May 22, 2023—Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced the U.S. Food and Drug Administration (FDA) has accepted
Lumicell™ DVS Pivotal Trial Results Published in NEJM Evidence and to Be Presented at ASBrS Assess Safety and Effectiveness of System for Identifying Residual Breast Cancer During Lumpectomy
NEWTON, Mass., April 27, 2023—Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced that results of the Investigation of Novel Surgical Imaging for
Lumicell Direct Visualization System Premarket Approval Application Submitted to U.S. FDA for Intraoperative Breast Cancer Detection and Removal
Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced a Premarket Approval (PMA) application for its Lumicell™ Direct Visualization System (DVS) has
Lumicell Submits New Drug Application for LUMISIGHT™ Optical Imaging Agent to U.S. FDA for Intraoperative Breast Cancer Detection and Removal
Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced a New Drug Application (NDA) for its LUMISIGHT™ Optical Imaging Agent has been
Events
San Antonio Breast Cancer Symposium®,
December 10-14, 2024
Henry B. Gonzalez Convention Center
Investors
